Galderma posted record H1 2026 net sales of $3.13B, with Injectable Aesthetics up 12.1%, plus new Restylane, Sculptra, and SkinBoosters milestones abroad.
Galderma reported record first-half 2026 net sales of $3.13 billion, up 24.6% at constant currency, with Injectable Aesthetics rising 12.1% to $1.44 billion. The company also logged new international milestones for Restylane SHAYPE, Sculptra, and SkinBoosters, and raised its full-year sales guidance.
Galderma, the Swiss dermatology company behind Dysport, Restylane, and Sculptra, said on July 22, 2026 that first-half net sales reached a record $3.134 billion, up 24.6% at constant currency. The result marked a company record for any six-month period. Injectable Aesthetics, the division most relevant to medspa patients, grew 12.1% at constant currency to $1.437 billion. Alongside the numbers, Galderma flagged fresh regulatory milestones for three of its aesthetic brands across Thailand, Australia, and China.
For US readers, an important caveat runs through the whole announcement: several of these milestones are approvals outside the United States and do not change what is legally available or FDA-approved domestically.
Within Injectable Aesthetics, neuromodulators contributed $826 million, up 13.4% at constant currency, while fillers and biostimulators added $611 million, up 10.5%. Dysport, Galderma's abobotulinumtoxinA wrinkle injection, is FDA-approved in the United States and drove much of the neuromodulator growth. Galderma also cited Relfydess, a ready-to-use liquid toxin that is approved in the EU but is not FDA-approved in the US, as a contributor in Europe. Relfydess is now cleared in 33 markets and, during the half, launched in Hong Kong as its first Asian market. On the strength of the half, Galderma raised its full-year 2026 guidance to 19 to 21% constant-currency growth, up from a prior range of 17 to 20%, and confirmed a core EBITDA margin of roughly 26% at constant currency.
The product news landed entirely outside the United States. Restylane SHAYPE, a hyaluronic acid filler, was cleared in Thailand for chin augmentation. Restylane is an FDA-approved HA filler family in the US, but this specific chin-augmentation clearance is a Thailand approval, not a US one. Sculptra, a poly-L-lactic acid biostimulator, won an Australian indication for body areas including the gluteal region, posterior thighs, decolletage, and upper arms, alongside a separate approval in India. In the US, Sculptra is FDA-approved for facial use only, so body use here is off-label and not FDA-approved. Finally, the SmartClick SkinBoosters syringe rolled out in China; SkinBoosters microdroplet treatments are not FDA-approved in the US.
A record earnings quarter reflects global demand, not expanded US options. If a provider markets Sculptra for the buttocks or body, or offers SkinBoosters, patients should understand those uses are off-label or not FDA-cleared in the US, where evidence and oversight differ from approved facial indications. Galderma's raised guidance signals confidence in continued injectable demand, but it does not accelerate any US filing, and the company has not given a timeline for any US regulatory filing on the newly approved international indications. What to watch is whether Galderma seeks US approval for any of these indications, how the neuromodulator and filler segments hold through the second half of 2026, and whether newer products like Relfydess reach the US market.